<DOC>
	<DOCNO>NCT00351221</DOCNO>
	<brief_summary>The trial investigate treatment growth failure child Noonan syndrome . Abnormalities growth hormone ( GH ) – insulin-like growth factor-I ( IGF-I ) axis result low IGF-I level suggest possible cause short stature see Noonan syndrome child . Administration investigational product intend bypass abnormality GH-IGF axis , hopefully improve body growth .</brief_summary>
	<brief_title>Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 Children With Noonan Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Noonan Syndrome</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . A diagnosis Noonan syndrome 2 . Height le 3rd percentile age sex ( height SDS &lt; 1.88 ) 3 . Basal IGFI less mean age sex ( IGFI SDS &lt; 0 ) 4 . Chronological age great 2 year 5 . Bone age ≤ 11 year boys , ≤ 10 year girls 6 . Prepubertal 7 . Documented pretreatment height velocity less mean age sex 1 . Clinically significant diseases 2 . Chronic illnesses 3 . Prior treatment rhIGF1</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>